Comparing INVO Fertility (NASDAQ:IVF) and Interpace Biosciences (OTCMKTS:IDXG)

Interpace Biosciences (OTCMKTS:IDXG) and INVO Fertility (NASDAQ:IVF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Interpace Biosciences and INVO Fertility, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interpace Biosciences	0	0	0	0	0.00
INVO Fertility	1	0	0	1	2.50

INVO Fertility has a consensus price target of $20.00, suggesting a potential upside of 880.39%. Given INVO Fertility’s stronger consensus rating and higher possible upside, analysts plainly believe INVO Fertility is more favorable than Interpace Biosciences.

Profitability

This table compares Interpace Biosciences and INVO Fertility’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	63.46%	493.02%	137.46%
INVO Fertility	-417.02%	N/A	-92.42%

Volatility & Risk

Interpace Biosciences has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.64, indicating that its share price is 164% more volatile than the S&P 500.

Institutional and Insider Ownership

5.7% of Interpace Biosciences shares are owned by institutional investors. Comparatively, 12.0% of INVO Fertility shares are owned by institutional investors. 5.5% of Interpace Biosciences shares are owned by company insiders. Comparatively, 0.7% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Interpace Biosciences and INVO Fertility”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.22	$24.58 million	($0.02)	-96.70
INVO Fertility	$6.53 million	0.51	-$9.10 million	($3,151.46)	0.00

Interpace Biosciences has higher revenue and earnings than INVO Fertility. Interpace Biosciences is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.